Риск развития дефицита железа повышается в 3.5 раза у пациентов, постоянно принимающих празолы (ИПП), и в 1.5 раза - если их прием периодический, по сравнению с пациентами, которые никогда их не принимали:
Adjusted odds ratio of ID in PPI "full" user (PFU) /defined as a subject who had received PPIs for a continuous duration of at least one year prior to the index date/ and PPI "limited" users (PLU) was a subject who intermittently received PPI therapy compared to PPI non-user (PNU) was 3.60 (95%CI, [3.32 - 3.91]) and 1.51 (95% CI, [1.44 - 1.58]). Positive dose-response and time-response relationships were observed.
---
J Intern Med. 2018 Aug 23.
Use of proton pump inhibitor and risk of iron deficiency: a population-based case-control study.
Tran-Duy A и соавт.
|